Wally Rapattoni

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 11

Top Topics

Randomized Controlled Trial

Chronic Kidney Disease

Acute Heart Failure

Top Venues

Diabetes, obesity & metabolism

Journal of the American Heart Association

This page only lists publications with an associated author ORCID identifier.

Publications

Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S Bajaj, G B John Mancini, Norman C Wong, April E Hebert, Fernando G Ang, Wally Rapattoni, Brendon L Neuen, Clare Arnott, Vlado Perkovic, Kenneth W Mahaffey
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 13 (3) (2024)
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S Bajaj, G B John Mancini, Norman C Wong, April E Hebert, Fernando G Ang, Wally Rapattoni, Brendon L Neuen, Clare Arnott, Vlado Perkovic, Kenneth W Mahaffey
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 13 (3) (2024)
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S Bajaj, G B John Mancini, Norman C Wong, April E Hebert, Fernando G Ang, Wally Rapattoni, Brendon L Neuen, Clare Arnott, Vlado Perkovic, Kenneth W Mahaffey
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 13 (3) (2024)
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S Bajaj, G B John Mancini, Norman C Wong, April E Hebert, Fernando G Ang, Wally Rapattoni, Brendon L Neuen, Clare Arnott, Vlado Perkovic, Kenneth W Mahaffey
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association (2024)
Abhinav Sharma, Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S Bajaj, G B John Mancini, Norman C Wong, April E Hebert, Fernando G Ang, Wally Rapattoni, Brendon L Neuen, Clare Arnott, Vlado Perkovic, Kenneth W Mahaffey
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 13 (3) (2024)
Tae Won Yi, Michelle M Y Wong, Brendon L Neuen, Clare Arnott, Paul Poirier, Jochen Seufert, April Slee, Wally Rapattoni, Fernando G Ang, David C Wheeler, Kenneth W Mahaffey, Vlado Perkovic, Adeera Levin
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: integrated analysis from the CANVAS Program and CREDENCE trial. Diabetes, obesity & metabolism (2023)
Abhinav Sharma, Pedro Marques, Brendon L Neuen, Robert A Fletcher, April E Hebert, Wally Rapattoni, Fernando G Ang, Clare Arnott, Adeera Levin, Subodh Verma, Vlado Perkovic, Kenneth W Mahaffey
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial. Diabetes, obesity & metabolism (2023)
Michael A Tsoukas, Vincent Woo, Sheldon W Tobe, April Slee, Wally Rapattoni, Fernando G Ang, Jochen Seufert, Brendon L Neuen, Clare Arnott, Kenneth W Mahaffey, David C Wheeler
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS Program and CREDENCE. Diabetes, obesity & metabolism (2023)
Vikas S Sridhar, Brendon L Neuen, Robert A Fletcher, April Slee, Fernando G Ang, Wally Rapattoni, Clare Arnott, David Z I Cherney, Vlado Perkovic, David C Wheeler, Adeera Levin
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials. Diabetes, obesity & metabolism (2023)
Wally Rapattoni, David Zante, Marko Tomas, Varun Myageri, Shane Golden, Prerna Grover, Ali Tehrani, Brad Millson, Sheldon W Tobe, Jennifer B Rose
A retrospective observational population-based study to assess the prevalence and burden of illness of type 2 diabetes with an estimated glomerular filtration rate < 90 mL/min/1.73 m2 in Ontario, Canada. Diabetes, obesity & metabolism 23 (4) (2021)
Vincent Woo, Alan Bell, Maureen Clement, Luis Noronha, Michael A Tsoukas, Fernando Camacho, Shana Traina, Natasha Georgijev, Matthew D Culham, Jennifer B Rose, Wally Rapattoni, Harpreet S Bajaj
CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice. Diabetes, obesity & metabolism 21 (3) (2018)